@MarsC,
I haven't missed the point at all. Please, let's keep this civil and keep our comments about how smart we might think each other is to ourselves. It does nothing for civil discussion.
My comments were not a discussion around FLT's valuation, which you appear to be attempting to pivot to. They were strictly limited to what net financial benefits the JobKeeper initiative is likely to have on FLT as a business, under the circumstances it currently finds itself in, that is all. Please, let's stay on point.
Btw, the existing IR system already provides a mechanism in which companies can stand down employees whereby the payroll (cash bleed) is reduced to nil for each employee stood down (ignoring leave drawdowns for the sake of this discussion). This cash preservation mechanism already exists. The JobKeeper initiative isn't really that novel in this regard. It's primarily designed to support employees, who would otherwise earn nil if they were stood down. That's why the financial benefits under that scheme are available regardless of whether the employee is active or stood down. The financial benefit conferred to any given company will depend on what that company is doing with its employees. If it stands down a great percentage of its workforce, as I am expecting with FLT, then the financial effect will will be largely neutral.
You are entitled to hold a different view of what FLT might do with its workforce but that most certainly doesn't mean that others have missed the point. Quite the contrary, actually.
It's all good, mate. I know it's stressful having the stock in suspension. Hopefully there's some positive news forthcoming soon about Skroo's plan for the way forward.
- Forums
- ASX - By Stock
- FLT
- How will the latest gov stimus help FLT
How will the latest gov stimus help FLT, page-37
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FLT (ASX) to my watchlist
(20min delay)
|
|||||
Last
$22.43 |
Change
0.480(2.19%) |
Mkt cap ! $4.957B |
Open | High | Low | Value | Volume |
$22.20 | $22.44 | $21.97 | $15.86M | 712.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 209 | $22.43 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$22.44 | 5304 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 2640 | 22.420 |
20 | 2274 | 22.410 |
9 | 1018 | 22.400 |
6 | 863 | 22.390 |
10 | 1114 | 22.380 |
Price($) | Vol. | No. |
---|---|---|
22.430 | 423 | 13 |
22.440 | 5626 | 9 |
22.450 | 9381 | 12 |
22.460 | 3675 | 6 |
22.470 | 1191 | 5 |
Last trade - 14.20pm 15/07/2024 (20 minute delay) ? |
Featured News
FLT (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online